Creso Pharma
CLOSED

FOR SOPHISTICATED AND PROFESSIONAL INVESTORS ONLY - Creso was created to bring pharmaceutical expertise and methodological rigour to the world of cannabis and deliver quality products to people and animals everywhere

CLOSED 26 November 2019
Share Price: $0.191Min Parcel: $20055Type: Ordinary ShareCode: CPH
Key points

Creso was created to bring pharmaceutical expertise and methodological rigour to the world of cannabis and deliver quality products to people and animals everywhere. Founded by a team of highly-experienced pharmaceutical executives, Creso set out to leverage cutting edge science and research to develop, register and commercialise innovative cannabis and hemp derived products. 

Creso has commercialised a range of products in human and animal health and has nine new products across both portfolios ready for launch in 2020. It has distribution agreements in a number of countries including Australia, New Zealand, the UK, South Africa, Switzerland, Brazil, and Israel.

Creso owns a 24,000sq ft fully GMP cannabis growing facility in Nova Scotia, Canada and has been granted a processing licence from Health Canada. First revenues from Mernova commenced in July 2019 and the facility is approaching full production capacity.

Please refer to the Company's ASX announcements for further information about the Company.

Website: www.cresopharma.com

 

Key Investment Highlights 

  • Three new animal health products are ready for launch in 2020 in the areas of stress, ageing pets and chronic pain for large animals (such as horses)
  • Six new hemp-oil/hemp-seed oil-based products are ready for launch in 2020 including: cannaQIX®NITE, cannaPEAL® and cannaPEAL®NITE targeted at sleep disturbances and stress, and cannaDOL®Revitalise targeted at muscle and joint revitalisation
  • Creso has entered into an agreement with Pharma Dynamics for the sole distribution rights of CannaQIX®10 in a number of African countries
  • Mernova Medical received a processing licence which allows it sell high quality oils and extracts from its trim, making it a fully vertically integrated facility with an annual capacity including 1,500kg of trim
  • Mernova Medical is in the process of obtaining EU GMP certification
  • Creso entered into a distribution agreement with Medleaf in New Zealand for a larger range of Creso’s products, building on an LOI signed in 2018

Term Sheet and Application Details will be emailed to Wholesale investors.